Journal article
IAEA contribution to the development of copper-64 radiopharmaceuticals for theranostic applications
International Atomic Energy Agency1
Bhabha Atomic Research Centre2
Atomic Energy Organization of Iran3
National Autonomous University of Mexico4
Ayub Medical College5
King Faisal Specialist Hospital and Research Centre6
Atomic Energy Commission of Syria7
University Medical Center Groningen8
University of Missouri9
University of Ferrara10
Westmead Hospital11
Clarity Pharmaceuticals12
Universidade Federal do Rio de Janeiro13
Université de Sherbrooke14
China National Nuclear Corporation15
Department of Health Technology, Technical University of Denmark16
Targeted Radionuclids, Hevesy and Dosimetry, Department of Health Technology, Technical University of Denmark17
Medical Isotopes, Hevesy and Dosimetry, Department of Health Technology, Technical University of Denmark18
...and 8 moreCopper-64 is a very attractive radioisotope with unique nuclear properties that allow using it as both a diagnostic and therapeutic agent, thus providing an almost ideal example of a theranostic radionuclide. A characteristic of Cu-64 stems from the intrinsic biological nature of copper ions that play a fundamental role in a large number of cellular processes.
Cu-64 is a radionuclide that reflects the natural biochemical pathways of Cu-64 ions, therefore, can be exploited for the detection and therapy of certain malignancies and metabolic diseases. Beside these applications of Cu-64 ions, this radionuclide can be also used for radiolabelling bifunctional chelators carrying a variety of pharmacophores for targeting different biological substrates.
These include peptide-based substrates and immunoconjugates as well as small-molecule bioactive moieties. Fueled by the growing interest of Member States (MS) belonging to the International Atomic Energy Agency (IAEA) community, a dedicated Coordinated Research Project (CRP) was initiated in 2016, which recruited thirteen participating MS from four continents.
Research activities and collaborations between the participating countries allowed for collection of an impressive series of results, particularly on the production, preclinical evaluation and, in a few cases, clinical evaluation of various 64Cu-radiopharmaceuticals that may have potential impact on future development of the field.
Since this CRP was finalized at the beginning of 2020, this short review summarizes outcomes, outputs and results of this project with the purpose to propagate to other MS and to the whole scientific community, some of the most recent achievements on this novel class of theranostic 64Cu-radiopharmaceticals.
Language: | English |
---|---|
Year: | 2020 |
Pages: | 338-345 |
ISSN: | 18271936 and 18244785 |
Types: | Journal article |
DOI: | 10.23736/S1824-4785.20.03302-6 |
ORCIDs: | Zhuravlev, Fedor |